Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 298

Results For "clinical"

2982 News Found

Dr. Reddy's initiates process for emergency use authorization of Sputnik V
News | February 20, 2021

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.


LupinLife Launches ayurvedic energy supplement
News | February 12, 2021

LupinLife Launches ayurvedic energy supplement

Be One is a 100% Ayurvedic health and wellness supplement.


Zydus completes enrolment for two Phase Ill trials of Desidustat
News | February 08, 2021

Zydus completes enrolment for two Phase Ill trials of Desidustat

The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.


Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
News | February 06, 2021

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.


WACKER acquires plasmid DNA Manufacturer Genopis
News | February 05, 2021

WACKER acquires plasmid DNA Manufacturer Genopis

WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).


Syngene Q3 revenue up 13% to Rs. 585 Cr
News | January 22, 2021

Syngene Q3 revenue up 13% to Rs. 585 Cr

EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.


Zydus eyes $6 bn market with strong COVID-19 portfolio
News | January 18, 2021

Zydus eyes $6 bn market with strong COVID-19 portfolio

With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential


Dr. Reddy’s gets approval for Sputnik V Phase 3 trial
News | January 16, 2021

Dr. Reddy’s gets approval for Sputnik V Phase 3 trial

The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.


Thermo Fisher completes acquisition of Henogen
News | January 16, 2021

Thermo Fisher completes acquisition of Henogen

Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business